Obesity trend watch: Companies aim for higher quality weight loss

While incretin-based therapies dominate the obesity market today, some companies are looking ahead to a future where the quality of weight loss matters as much as the quantity — and prioritizing targets and programs that could help realize that vision.

GLP-1R agonist monotherapies and combinations form the backbone of the current obesity treatment paradigm because they can deliver substantial weight loss in a short time frame. This not only gives patients visible results, but also can lower their risk from co-morbidities such as cardiovascular disease or kidney complications...